

# Justin T Jordan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/573774/publications.pdf>

Version: 2024-02-01

74  
papers

1,947  
citations

331670

21  
h-index

289244

40  
g-index

78  
all docs

78  
docs citations

78  
times ranked

2515  
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. <i>Genetics in Medicine</i> , 2021, 23, 1506-1513.	2.4	290
2	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 492-516.	1.6	261
3	Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. <i>Blood</i> , 2019, 133, 2212-2221.	1.4	207
4	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1048-1057.	7.0	129
5	Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. <i>Genetics in Medicine</i> , 2019, 21, 867-876.	2.4	62
6	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. <i>Blood</i> , 2022, 139, 2306-2315.	1.4	62
7	Increased Risk of Cerebrovascular Disease Among Patients With Neurofibromatosis Type 1. <i>Stroke</i> , 2016, 47, 60-65.	2.0	59
8	Glioblastoma care in the elderly. <i>Cancer</i> , 2016, 122, 189-197.	4.1	53
9	The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. <i>Oncologist</i> , 2020, 25, e1109-e1116.	3.7	53
10	Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2006-2006.	1.6	49
11	A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. <i>Oncotarget</i> , 2015, 6, 16981-16997.	1.8	46
12	Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. <i>Cancer</i> , 2019, 125, 3692-3698.	4.1	42
13	Genotype-targeted local therapy of glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8388-E8394.	7.1	40
14	Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2010-2010.	1.6	38
15	Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11008.	1.0	35
16	Hospice utilization in patients with malignant gliomas. <i>Neuro-Oncology</i> , 2018, 20, 538-545.	1.2	33
17	Characteristics of graduating US allopathic medical students pursuing a career in neurology. <i>Neurology</i> , 2019, 92, e2051-e2063.	1.1	31
18	Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines*. <i>Neuro-Oncology</i> , 2019, 21, 424-427.	1.2	27

#	ARTICLE	IF	CITATIONS
19	Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 2271-2276.	1.6	27
20	Education Research: Neurology resident education. <i>Neurology</i> , 2016, 86, e112-7.	1.1	25
21	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. <i>Neuro-Oncology</i> , 2019, 21, 596-605.	1.2	25
22	Primary dural lymphomas: Clinical presentation, management, and outcome. <i>Cancer</i> , 2020, 126, 2811-2820.	4.1	24
23	EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. <i>Neuro-Oncology</i> , 2018, 20, 1185-1196.	1.2	22
24	Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines. <i>Journal of Clinical Oncology</i> , 2019, 37, 1130-1135.	1.6	22
25	Pain correlates with germline mutation in schwannomatosis. <i>Medicine (United States)</i> , 2018, 97, e9717.	1.0	20
26	Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. <i>BMC Health Services Research</i> , 2018, 18, 668.	2.2	19
27	Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 152, 515-522.	2.9	18
28	Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs. <i>Genes</i> , 2020, 11, 387.	2.4	16
29	The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 61.	2.7	15
30	First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial. <i>Journal of Neuro-Oncology</i> , 2019, 143, 505-513.	2.9	14
31	First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis. <i>Journal of Neuro-Oncology</i> , 2017, 131, 413-419.	2.9	13
32	A rapid genotyping panel for detection of primary central nervous system lymphoma. <i>Blood</i> , 2021, 138, 382-386.	1.4	13
33	Unrecognized cobalamin deficiency, nitrous oxide, and reversible subacute combined degeneration. <i>Neurology: Clinical Practice</i> , 2014, 4, 358-361.	1.6	12
34	Benign Intracranial Tumors. <i>Neurologic Clinics</i> , 2018, 36, 501-516.	1.8	11
35	Opinion & Special Articles: Maximizing Inclusiveness and Diversity Through Virtual Residency Applications and Interviews. <i>Neurology</i> , 2021, 97, 647-650.	1.1	11
36	Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. <i>Neuro-Oncology Practice</i> , 2018, 5, 64-68.	1.6	10

#	ARTICLE	IF	CITATIONS
37	First report of factors associated with satisfaction in patients with neurofibromatosis. American Journal of Medical Genetics, Part A, 2017, 173, 671-677.	1.2	9
38	Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neuro-Oncology Advances, 2020, 2, vdaa157.	0.7	8
39	mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. Journal of Biological Chemistry, 2021, 296, 100157.	3.4	8
40	Neurofibromatosis. Hematology/Oncology Clinics of North America, 2022, 36, 253-267.	2.2	8
41	Quality improvement in neurology. Neurology, 2018, 90, 652-658.	1.1	7
42	Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT. Journal of Neuro-Oncology, 2018, 136, 335-342.	2.9	7
43	Attracting neurology's next generation. Neurology, 2020, 95, e1080-e1090.	1.1	7
44	Validating Techniques for Measurement of Cutaneous Neurofibromas. Neurology, 2021, 97, S32-S41.	1.1	6
45	Quality improvement in neurology: Neuro-Oncology Quality Measurement Set. Neuro-Oncology, 2018, 20, 531-537.	1.2	5
46	Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosis. Patient Education and Counseling, 2021, 104, 808-814.	2.2	5
47	Contemporary Neuroscience Core Curriculum for Medical Schools. Neurology, 2021, 97, 675-684.	1.1	5
48	Magnetic Resonance Imaging Observations in Primary Central Nervous System Lymphoma. JAMA Neurology, 2014, 71, 918.	9.0	4
49	Neurologic Immune-Related Adverse Events in Oncology Care. JAMA Neurology, 2016, 73, 907.	9.0	4
50	Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.. Journal of Clinical Oncology, 2021, 39, 2024-2024.	1.6	4
51	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. Neuro-Oncology, 2022, 24, 331-357.	1.2	4
52	Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis. American Journal of Medical Genetics, Part A, 2022, 188, 2672-2683.	1.2	4
53	International Issues: Obtaining an adult neurology residency position in the United States. Neurology, 2014, 82, e112-5.	1.1	3
54	Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis. American Journal of Medical Genetics, Part A, 2022, 188, 2413-2420.	1.2	3

#	ARTICLE	IF	CITATIONS
55	Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2030-2030.	1.6	3
56	Teaching Neuro <i>Images</i> : Brain mass with hilar adenopathy. Neurology, 2014, 82, e161-2.	1.1	2
57	INNV-20. UTILITY OF TELEHEALTH FOR SPECIALTY NEUROFIBROMATOSIS (NF) CARE. Neuro-Oncology, 2018, 20, vi142-vi142.	1.2	2
58	DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI. IEEE Journal of Biomedical and Health Informatics, 2021, PP, 1-1.	6.3	1
59	INNV-04. A MULTI-INSTITUTIONAL CLINICAL AND MRI REPOSITORY OF NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PERIPHERAL NERVE SHEATH TUMORS. Neuro-Oncology, 2021, 23, vi105-vi106.	1.2	1
60	Practical guidance for telemedicine use in neuro-oncology. Neuro-Oncology Practice, 2022, 9, 91-104.	1.6	1
61	Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists. Orphanet Journal of Rare Diseases, 2022, 17, 44.	2.7	1
62	Review of<i>Controversies in Neuro-Oncology: Best Evidence Medicine for Brain Tumor Surgery</i>. JAMA Neurology, 2014, 71, 1195.	9.0	0
63	HCP-12IMPROVING THE EFFICIENCY OF MOLECULAR TESTING FOR EXPEDITED BRAIN TUMOR PATIENT MANAGEMENT AND CLINICAL TRIAL ENROLLMENT. Neuro-Oncology, 2015, 17, v103.4-v104.	1.2	0
64	CSIG-42. HIGH THROUGHPUT KINOME AND TRANSCRIPTOME ANALYSES REVEAL NOVEL THERAPEUTIC TARGETS IN NF2-DEFICIENT MENINGIOMA. Neuro-Oncology, 2018, 20, vi52-vi52.	1.2	0
65	NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE. Neuro-Oncology, 2018, 20, vi191-vi191.	1.2	0
66	NIMG-66. LONG-TERM FOLLOW-UP OF NEUROFIBROMATOSIS TYPE 1 PATIENTS USING WHOLE-BODY MRI DEMONSTRATES DYNAMIC CHANGES IN INTERNAL NEUROFIBROMA SIZE. Neuro-Oncology, 2019, 21, vi176-vi176.	1.2	0
67	NIMG-07. LONG-TERM FOLLOW-UP OF SCHWANNOMA GROWTH BEHAVIOR IN ADULT NEUROFIBROMATOSIS TYPE 2 AND SCHWANNOMATOSIS PATIENTS USING WHOLE-BODY MRI. Neuro-Oncology, 2020, 22, ii148-ii148.	1.2	0
68	Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2037-2037.	1.6	0
69	MRI changes in patients with newly diagnosed glioblastoma treated as part of a phase II trial with bavituximab, radiation, and temozolomide.. Journal of Clinical Oncology, 2020, 38, 2546-2546.	1.6	0
70	NIMG-08. A MULTI-CENTER RADIOMICS-BASED MODEL TO DIFFERENTIATE BETWEEN NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS AND MALIGNANT PERIPHERAL NERVE SHEATH TUMORS. Neuro-Oncology, 2021, 23, vi128-vi129.	1.2	0
71	NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii138-ii139.	1.2	0
72	CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2020, 22, ii40-ii40.	1.2	0

#	ARTICLE	IF	CITATIONS
73	CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION. <i>Neuro-Oncology</i> , 2021, 23, vi72-vi72.	1.2	0
74	Abstract 6084: Recurrent genomic patterns of MPNST evolution correlate with clinical outcome. <i>Cancer Research</i> , 2022, 82, 6084-6084.	0.9	0